Product nameAnti-pan Synuclein antibody
See all pan Synuclein primary antibodies
DescriptionRabbit polyclonal to pan Synuclein
SpecificityDetects endogenous levels of total Synuclein protein. This antibody recognises all forms of synuclein (alpha, beta and gamma).
Tested applicationsSuitable for: WB, IHC-P, ELISAmore details
Species reactivityReacts with: Rat, Human
Predicted to work with: Mouse
Synthetic peptide within Human pan Synuclein aa 15-64. The exact sequence is proprietary. Synthetic peptide derived from human synuclein.
- WB: Extracts from LOVO cells. IHC-P: Human brain tissue.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol, 0.87% Sodium chloride, PBS
Without Mg+2 and Ca+2
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab53726 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/1000. Detects a band of approximately 14 kDa (predicted molecular weight: 14 kDa).|
|IHC-P||Use at an assay dependent concentration.|
RelevanceSynucleins are small, soluble proteins expressed primarily in neural tissue and in certain tumors. The family includes three known proteins: alpha, beta and gamma synucleins. Synuclein-alpha is primarily localized at the presynaptic region of axons and it may be involved in the regulation of dopamine release and transport. However, it can form filamentous aggregates that are the major non amyloid component of intracellular inclusions in several neurodegenerative diseases (synucleinopathies). Synuclein-alpha may induce fibrillization of the microtubule-associated protein tau and it reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase 3 activation. Synuclein-alpha is involved in Parkinson's disease, Lewy body dementia, Brain iron accumulation type 1 (NBIA1, also called Hallervorden-Spatz syndrome) and it is a major non-amyloid component of the deposits associated with Alzheimer's disease. Synuclein-beta may be a regulator of the SNCA aggregation process. It protects neurons from staurosporine and 6 hydroxy dopamine (6OHDA)-stimulated caspase activation that also involves p53 and contributes to restore the SNCA anti-apoptotic function abolished by 6OHDA. Gamma synuclein is found primarily in the peripheral nervous system and retina. High levels of expression have been identified in advanced breast carcinomas suggesting a correlation between overexpression of SNCG and breast tumor development.
Cellular localizationNeuronal cytosol and presynaptic terminals
- BCSG1 antibody
- beta synuclein antibody
- Breast cancer specific gene 1 protein antibody
All lanes : Anti-pan Synuclein antibody (ab53726) at 1/500 dilution
Lane 1 : rat heart lysate
Lane 2 : rat heart lysate with immunizing peptide
Lysates/proteins at 5 µg per lane.
All lanes : Alkaline Phosphatase Goat Anti-Rabbit IgG (H+L)
Predicted band size: 14 kDa
Observed band size: 14 kDa
Ab53726 at 1/50 dilution, staining paraffin embedded human brain in the presence (right) or absence (left) of blocking peptide.
This product has been referenced in:
- Medeiros AT et al. a-Synuclein Dimers Impair Vesicle Fission during Clathrin-Mediated Synaptic Vesicle Recycling. Front Cell Neurosci 11:388 (2017). Read more (PubMed: 29321725) »
- Busch DJ et al. Acute increase of a-synuclein inhibits synaptic vesicle recycling evoked during intense stimulation. Mol Biol Cell 25:3926-41 (2014). Read more (PubMed: 25273557) »